BioCentury
ARTICLE | Product Development

In with the ALK Crowd

Pfizer's crizotinib for NSCLC spurs Tesaro's ALK inhibitor deal with Amgen

April 25, 2011 7:00 AM UTC

Pfizer Inc.'s crizotinib has provided POC that targeting ALK can significantly improve response in a small subset of non-small cell lung cancer patients compared to current treatments. While the pharma completes it NDA submission, other companies are lining up behind it with second-generation programs that they believe will be more selective and more potent.

One of them is a newco, Tesaro Inc., which in-licensed Amgen Inc.'s ALK program last month...